In the final episode, Overcoming Barriers and Future Integration of Subcutaneous Therapies in Lung Cancer, the panelists ...

A randomized trial finds weekly extended-release buprenorphine yields neonatal outcomes comparable to sublingual treatment.

Avtozma is among the first wave of tocilizumab biosimilars with both intravenous and subcutaneous formulations approved and ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

What causes it, how it looks on different skin tones, and an available biologic treatment option that can be used with or ...

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat adults with moderate-to-severe bullous pemphigoid: Paris Wednesday, March 25, 2026, 09:00 Hrs [IST] T ...

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...

Dr Reddy’s Labs launches India’s first DCGI-approved semaglutide injection ‘Obeda’ for type 2 diabetes: Our Bureau, Mumbai Saturday, March 21, 2026, 13:30 Hrs [IST] Dr Red ...

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidApproval in ...

From standard medications to advanced drug delivery, surgery, and regenerative approaches, Parkinson's treatment options in ...

Dr Reddy's Laboratories has announced the launch of its injectable semaglutide under the brand name Obeda, marking an important step in expanding access to GLP-1 receptor agonist-based therapy for the ...